Melanoma trials in Germany

In Germany 49 Also abroad 579

49 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Where
Berlin, Frankfurt am Main, Goettingen, Heidelberg, Tübingen
Age
18 years and over
People
15 worldwide
Run by
Valo Therapeutics Oy
See details and how to joinNCT05492682 · EU 2024-517580-23-00
Phase 2Taking people
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Where
Hamburg, Heidelberg, Leipzig, Mainz, München, Würzburg
Age
18 years and over
People
254 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07492680
Phase 4Taking people
Dabrafenib and/or Trametinib Rollover Study
Where
Augsburg, Essen, Hamburg, Heidelberg, Mannheim
Age
18 years to 100 years
People
100 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT03340506 · EU 2023-509318-13-00
No phaseTaking people
High-precision Radiosurgery Followed by Minimally Invasive Surgical Approach in Patients With High-prominence Uveal Melanoma: Modern Radiation Techniques and Outcomes
Where
Essen
Age
18 years and over
People
250
Run by
University Hospital, Essen
See details and how to joinNCT07913412
Phase 3Taking people
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
Where
Berlin, Bonn, Cologne, Dresden, Erlangen, Essen, Frankfurt Am Main, Hamburg, Heidelberg, Leipzig, Mainz
Age
18 years and over
People
450 worldwide
Run by
Immatics US, Inc.
See details and how to joinNCT06743126 · EU 2024-517062-42-00
Phase 2Taking people
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Where
Frankfurt am Main, Giessen
Age
18 years and over
People
750 worldwide
Run by
DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Frankfurt
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Berlin, Dresden, Heidelberg, Heilbronn, Leipzig, Mainz, Muenster
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
No phaseTaking people
Development and Multi-Centre Validation of a Novel Non-Invasive Melanoma Molecular Diagnostic Test
Where
Tübingen
Age
18 years and over
People
2,000 worldwide
Run by
Mitra Bio
See details and how to joinNCT07883954
Phase 1/2Taking people
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies
Where
Berlin, Cologne, Erlangen, Goettingen, Muenster, Munich, Tuebingen, Wuerzburg
People
40
Run by
Miltenyi Biomedicine GmbH
See details and how to joinNCT06508775 · EU 2022-501648-14-00
Phase 1/2Taking people
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Where
Berlin, Essen, Mainz, München, Tübingen
Age
18 years and over
People
1,438 worldwide
Run by
BioNTech SE
See details and how to joinNCT07070232 · EU 2024-517261-16-00
Phase 2/3Taking people
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Where
Berlin, Buxtehude, Dresden, Erfurt, Erlangen, Gera, Halle (Saale), Hamburg, Kiel, Leipzig, Ludwigshafen Am Rhein, Luebeck, Magdeburg, Mainz, Mannheim, Marburg, Minden, Muenster, Nuremberg, Tuebingen, Wuerzburg
Age
18 years and over
People
740 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT06697301 · EU 2024-512659-19-00
Phase 2Not yet taking people in Germany
PHOENIX - ECP: Extracorporeal PHotopheresis for immune-related cOlitis and/or hEpatitis in advanced melaNoma with inadequate response to steroId eXposure
Where
Berlin, Cologne, Dresden, Essen, Freiburg im Breisgau, Halle (Saale), Luebeck, Mainz, Mannheim, Munich
Age
18 years and over
People
46 worldwide
Run by
Therakos Europe Limited
See details and how to join2026-526261-14-00 · EU 2026-526261-14-00
Phase 2Taking people
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
Where
Cologne, Essen, Frankfurt am Main, Hamburg, Heidelberg
Age
18 years and over
People
160 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06961006
Phase 3Taking people
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Where
Berlin, Dresden, Hamburg, Lübeck, Munich, Würzburg
Age
18 years to 70 years
People
670 worldwide
Run by
Iovance Biotherapeutics, Inc.
See details and how to joinNCT05727904 · EU 2022-503140-41-00
Phase 2Taking people
Early detection of side effects in patients with metastatic melanoma receiving immune checkpoint inhibitor therapy by investigation of the CD8+ immune infiltrate using [89Zr]Zr-Df-IAB22M2C-PET
Where
Tuebingen
Age
18 years and over
People
35
Run by
Universitaetsklinikum Tuebingen AöR
See details and how to join2024-512219-37-00 · EU 2024-512219-37-00
Phase 2Taking people
Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma
Where
Berlin
Age
18 years and over
People
19 worldwide
Run by
Grupo Español Multidisciplinar de Melanoma
See details and how to joinNCT07057596 · EU 2023-509076-42-00
No phaseTaking people
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Where
Hamburg, Heilbronn, Munich
Age
18 years and over
People
2,285 worldwide
Run by
Guardant Health, Inc.
See details and how to joinNCT05059444
Phase 2Taking people
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients
Where
Essen, Freiburg im Breisgau, Kiel, Tuebingen
Age
18 years and over
People
162 worldwide
Run by
Philogen S.p.A.
See details and how to joinNCT06284590 · EU 2024-519326-20-00
No phaseTaking people
Social Prescriptions and Micro-Learning to Improve Care for Cancer Patients and Their Support Persons
Where
Augsburg, Bayreuth, Berlin, Cologne, Erlangen, Regensburg, Würzburg
Age
18 years and over
People
384
Run by
University of Regensburg
See details and how to joinNCT07788729
No phaseTaking people
Gustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition Intervention
Where
Augsburg, Erlangen, München, Regensburg, Würzburg
Age
18 years and over
People
198
Run by
Wuerzburg University Hospital
See details and how to joinNCT07649681
Phase 3Enrolling by invitation
A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma
Where
Berlin, Essen, Hamburg, Munich
Age
18 years and over
People
100 worldwide
Run by
Aura Biosciences
See details and how to joinNCT07338968 · EU 2025-524405-33-00
Phase 1/2Taking people
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Where
Dresden, Essen, Frankfurt, Ulm, Würzburg
Age
18 years and over
People
1,109 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT04895709
Phase 1Taking people
A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
Where
Bochum, Cologne, Marburg, Muenster, Munich, Wuerzburg
Age
18 years and over
People
21
Run by
Kupando GmbH
See details and how to joinNCT07600476 · EU 2025-522402-21-00
No phaseTaking people
Clinical Study on High-fiber Diet and Short-term Fasting in Melanoma Under Immunotherapy With Checkpoint Inhibition
Where
Berlin
Age
18 years and over
People
60
Run by
Charite University, Berlin, Germany
See details and how to joinNCT07680452